Status | Study |
Recruiting |
Study Name: TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Condition: Multicentric Castleman Disease Date: 2017-01-31 Interventions: Drug: Thalidomide, cyclophosphamide and prednisone |
Recruiting |
Study Name: Castleman Disease Collaborative Network Biobank Condition: Castleman Disease Castleman's Disease Giant Lymph Node Hyp Date: 2016-08-15 Interventions: Other: Sample Collection Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA e |
Recruiting |
Study Name: Unlock the Cell: Castleman's Disease Flow Cytometry Study Condition: Castleman Disease Angiofollicular Lymphoid Hyperplasia GLN Date: 2016-07-15 Interventions: Procedure: Blood draw/buccal swab The research project will need a blood sample of no more than 50mL per |
Recruiting |
Study Name: International Registry for Patients With Castleman Disease Condition: Castleman Disease Castleman's Disease Giant Lymph Node Hyp Date: 2016-06-22 |
Recruiting |
Study Name: Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Condition: Kaposi Sarcoma Date: 2016-01-20 Interventions: Drug: liposomal doxorubicin li |
Withdrawn |
Study Name: Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Condition: Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease Date: 2014-08-27 Interventions: Drug: Pomalidomide Part A: 5 m |
Terminated |
Study Name: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Condition: Adult B Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Date: 2014-04-07 Interventions: Drug: Ibrutinib Given PO |
Recruiting |
Study Name: Tocilizumab for KSHV-Associated Multicentric Castleman Disease Condition: Castleman Disease Castleman's Disease Giant Lymph Node Hyp Date: 2011-09-24 Interventions: Drug: Zidovudine Zidovudine (A |
Active, not recruiting |
Study Name: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Condition: Multicentric Castleman's Disease Date: 2011-04-21 Interventions: Drug: Siltuximab Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. |
Completed |
Study Name: A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Condition: Castleman's Disease Date: 2010-08-13 Interventions: Drug: tocilizumab [RoActemra/Actemra] maintenance dose |